MLYS Stock Analysis: Mineralys Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.060m USD | 12M Return: -50.1% | US6031701013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 33.0M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 3.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is a U.S.-based biopharmaceutical company focused on developing therapies for diseases driven by dysregulated aldosterone. The company is headquartered in Radnor, Pennsylvania, was incorporated in 2019, and went public in February 2023. It was formerly known as Catalys SC1, Inc. before adopting its current name in May 2020.
Mineralys lead product candidate is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor being studied for cardiorenal conditions including hypertension, chronic kidney disease, and obstructive sleep apnea. As a clinical-stage biotechnology company, Mineralys operates within the health care sector and concentrates its efforts on a single proprietary therapeutic candidate rather than a diversified product portfolio.
- Lorundrostat Phase 3 hypertension data readout expected
- FDA regulatory pathway for lorundrostat advances
- Cash runway funds lorundrostat through pivotal trials
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.49 > 0.02 and ΔFCF/TA 3.92 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.21 > 3% & CFO -138.8m > Net Income -349.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 34.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (84.7m) vs 12m ago 29.45% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.01%; Δ -0.01% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.97 (Total Current Assets 665.8m - Total Current Liabilities 19.3m) / Total Assets 667.9m |
| B: -1.10 (Retained Earnings -737.6m / Total Assets 667.9m) |
| C: -0.70 (EBIT TTM -349.6m / Avg Total Assets 501.8m) |
| D: 4.71 (Book Value of Equity 550.9m / Total Liabilities 116.9m) |
| Altman-Z'' = 3.02 = A |
As of October 16, 2026, the stock is trading at USD 21.64 with a total of 1,093,902 shares traded. Over the past week, the price has changed by -3.31%, over one month by -25.15%, over three months by -20.76% and over the past year by -50.08%.
Current recommended Stop Loss: 19.90 (which is 8% or 1.2 ATR below the current price).
Mineralys Therapeutics has received a consensus analysts rating of 4.80. Therefore, it is recommended to buy MLYS.
- StrongBuy: 9
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 48.5 | 124.1% |
P/B = 4.3167
Revenue TTM = 0.0 USD
EBIT TTM = -349.6m USD
EBITDA TTM = -349.5m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 97.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -550.9m USD (calculated: Debt 97.6m - CCE 648.5m)
Enterprise Value = 1.51b USD (2.06b + Debt 97.6m - CCE 648.5m)
Interest Coverage Ratio = unknown (Ebit TTM -349.6m / Interest Expense TTM 0.0)
EV/FCF = -4.65x (Enterprise Value 1.51b / FCF TTM -324.5m)
FCF Yield = -21.50% (FCF TTM -324.5m / Enterprise Value 1.51b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 59.0k) / Revenue TTM)
Tobins Q-Ratio = 2.26 (Enterprise Value 1.51b / Total Assets 667.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 97.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -276.2m (EBIT -349.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 32.66 (Total Current Assets 665.8m / Total Current Liabilities 20.4m)
Debt / Equity = 0.18 (Debt 97.6m / totalStockholderEquity, last quarter 550.9m)
Debt / EBITDA = 1.58 (negative EBITDA) (Net Debt -550.9m / EBITDA -349.5m)
Debt / FCF = 1.70 (negative FCF - burning cash) (Net Debt -550.9m / FCF TTM -324.5m)
Total Stockholder Equity = 603.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -69.67% (Net Income -349.6m / Total Assets 667.9m)
RoE = -57.97% (Net Income TTM -349.6m / Total Stockholder Equity 603.0m)
RoCE = -53.90% (EBIT -349.6m / Capital Employed (Total Assets 667.9m - Current Liab 19.3m))
RoIC = -42.58% (negative operating profit) (NOPAT -276.2m / Invested Capital 648.5m)
WACC = 6.84% (E(2.06b)/V(2.16b) * Re(7.16%) + D(97.6m)/V(2.16b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 7.16% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.50 | Cagr: 32.61%
[DCF] Fair Price = unknown (Cash Flow -324.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.53 | Chg30d=+5.23% | Revisions=+22% | Analysts=7
EPS current Year (2026-12-31): EPS=-4.43 | Chg30d=-97.81% | Revisions=-70% | GrowthEPS=-93.4% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.50 | Chg30d=-19.26% | Revisions=-30% | GrowthEPS=+43.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -35% (up=6, down=14)